Research on patients with renal cell carcinoma (RCC) found that blocking the TIM-3 pathway could inhibit the activation of the TIM-3 pathway to restore the proliferation of CD4+ and CD8+ TILs and increase the production of IFN-γ [81]. This evidence concerns the gene CD8A and renal cell carcinoma.